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Abstract
Background: Differentiating infection from inflammation in acute pancreatitis is difficult, leading to overuse of
antibiotics. Procalcitonin (PCT) measurement is a means of distinguishing infection from inflammation as levels
rise rapidly in response to a pro-inflammatory stimulus of bacterial origin and normally fall after successful
treatment. Algorithms based on PCT measurement can differentiate bacterial sepsis from a systemic
inflammatory response. The PROCalcitonin-based algorithm for antibiotic use in Acute Pancreatitis (PROCAP)
trial tests the hypothesis that a PCT-based algorithm to guide initiation, continuation and discontinuation of
antibiotics will lead to reduced antibiotic use in patients with acute pancreatitis and without an adverse
effect on outcome.
Methods: This is a single-centre, randomised, controlled, single-blind, two-arm pragmatic clinical and cost-
effectiveness trial. Patients with a clinical diagnosis of acute pancreatitis will be allocated on a 1:1 basis to
intervention or standard care. Intervention will involve the use of a PCT-based algorithm to guide antibiotic
use. The primary outcome measure will be the binary outcome of antibiotic use during index admission.
Secondary outcome measures include: safety non-inferiority endpoint all-cause mortality; days of antibiotic
use; clinical infections; new isolates of multiresistant bacteria; duration of inpatient stay; episode-related
mortality and cause; quality of life (EuroQol EQ-5D); and cost analysis. A 20% absolute change in antibiotic
use would be a clinically important difference. A study with 80% power and 5% significance (two-sided)
would require 97 patients in each arm (194 patients in total): the study will aim to recruit 200 patients.
Analysis will follow intention-to-treat principles.
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Discussion: When complete, PROCAP will be the largest randomised trial of the use of a PCT algorithm to guide
initiation, continuation and cessation of antibiotics in acute pancreatitis. PROCAP is the only randomised trial to date to
compare standard care of acute pancreatitis as defined by the International Association of Pancreatology/American
Pancreatic Association guidelines to patients having standard care but with all antibiotic prescribing decisions based on
PCT measurement.
Trial registration: International Standard Randomised Controlled Trial Number, ISRCTN50584992. Registered on 7
February 2018.
Keywords: Acute pancreatitis, Antibiotics, Procalcitonin,
Background
Overuse of antibiotics and the resultant emergence
of multidrug-resistant organisms is a potent threat
to the welfare of humanity in the twenty-first cen-
tury [1, 2]. Acute pancreatitis is an inflammatory
disorder of the pancreas with an incidence of 150–
420 cases per million [3] and an overall case-fatality
rate of 4–6% [4, 5]. In addition to being a significant
cause of death, severe acute pancreatitis (SAP) is as-
sociated with prolonged critical care occupancy,
lengthy in-patient stay and slow rehabilitation [6].
SAP is characterised by necrosis of pancreatic tissue
which with bacterial colonisation leads to infected
necrosis [7]. Antimicrobial therapy to prevent infec-
tion of necrosis in acute pancreatitis has been evalu-
ated in a series of randomised controlled trials, with
overall findings demonstrating a lack of benefit re-
ported in meta-analyses and a Cochrane systematic
review [8–10].
Correct use of antibiotics is important in patients with in-
fected necrosis but use in those with systemic inflammation
in acute pancreatitis is non-therapeutic and possibly harm-
ful [11]. Discriminating between pancreatic infection and
inflammation is difficult, with neither clinical assessment
nor markers of inflammation (such as leukocyte count or
C-reactive protein) being sufficiently accurate [12]. As a re-
sult there is overuse of antibiotics for suspected infection in
acute pancreatitis, with up to two-thirds of patients receiv-
ing at least one course of antibiotics during their admission
[13]. Antibiotic overuse in acute pancreatitis is widespread
not only in the United Kingdom’s National Health Service
(NHS) [14] but also worldwide [15–18]. Overuse of antibi-
otics in acute pancreatitis is associated with the emergence
of resistant organisms, antibiotic-related side effects, com-
promised treatment efficacy and unnecessary health care
costs. Nationally, the National Confidential Enquiry into
Patient Outcome and Death (NCEPOD) [19] undertook
the largest survey to date of the treatment of acute pancrea-
titis in the NHS. “Treat the Cause”, published in 2016, rec-
ommends better support for clinicians making bedside
decisions about the use of antibiotics [19]. Specifically, the
report highlights the need for assistance in differentiating
infection from inflammation and better evidence for initi-
ation, continuation and discontinuation of antibiotics in
acute pancreatitis.
One method of distinguishing infection from inflamma-
tion is measurement of procalcitonin (PCT) [20]. Historic-
ally, calcitonin peptides were thought to be responsible for
calcium homeostasis but this is now thought to be a rela-
tively minor physiological role, and a more contemporary
appraisal is that procalcitonin is a “hormokine”, sharing
characteristics of both hormones and cytokines and having
roles in maintaining vascular endothelial tone in response
to bacterial infection [20]. The procalcitonin level in the
bloodstream of healthy individuals is below the limit of de-
tection (10 pg/ml) using clinical assays. Procalcitonin levels
rise rapidly in response to a pro-inflammatory stimulus of
bacterial origin and normally fall after successful treatment
[21]. PCT is more sensitive than clinical assessment and
routine laboratory markers of sepsis (such as leukocyte
count and C-reactive protein) in detecting pancreatic infec-
tion [22]. Algorithms based on measurement of procalcito-
nin have emerged as a means of differentiating bacterial
sepsis from a systemic inflammatory response in a wide
range of settings [23].
A recent Health Technology Assessment (HTA) re-
port evaluated procalcitonin testing as a guide to
antibiotic therapy and concluded that further studies
are needed before widespread adoption [24]. PCT
has also been evaluated as a biomarker in SAP,
mainly for early prediction of severity and for identi-
fication of patients with a high risk of infected pan-
creatic necrosis [25].
Qu et al. [26] reported the results of the only ran-
domised controlled trial of a procalcitonin algorithm
in severe acute pancreatitis: a single-centre study of
71 patients from China. They compared a PCT-based
algorithm for guidance of antibiotic use to routine
care in patients with acute pancreatitis. The duration
of antibiotic treatment in the PCT-guided group was
significantly shorter (10.9 ± 2.8 vs 16.1 ± 2.5 days, p <
0.001) without any adverse effects on outcome. Dur-
ation of intensive care treatment, overall hospital
stay and cost of care were significantly reduced in
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the PCT-guided group. However, all patients in the
control arm were given antibiotics for up to 14 days,
which does not reflect current international guideline
recommendations. Thus, the findings of this study
need to be reproduced in a setting where antibiotic
use follows contemporary practice before procalcito-
nin-based algorithms can be recommended to guide
antibiotic use in acute pancreatitis.
The PROCalcitonin-based algorithm for antibiotic
use in Acute Pancreatitis (PROCAP) trial tests the hy-
pothesis that a procalcitonin-based algorithm to guide
initiation, continuation and discontinuation of antibi-
otics will lead to reduced antibiotic use in patients




This is a single-centre, randomised, controlled, single-
blind, two-arm phase III pragmatic clinical and cost-
effectiveness trial. Patients will be allocated on a 1:1
basis to intervention and control. Patients, but not
clinicians, will be blind to their allocation.
Participants
Participants will be patients with a clinical diagnosis
of acute pancreatitis admitted to the hepato-pan-
creato-biliary (HPB) service of the Manchester Royal
Infirmary (MRI). The MRI is the regional specialist
HPB service for the Greater Manchester and Chesh-
ire region, a conurbation of 3.2 million people. Pa-
tients admitted directly to the service and those
arriving as tertiary transfers from other hospitals will
be included as separate strata within the trial design.
Inclusion criteria
Adult patients presenting with acute pancreatitis ad-
mitted or referred to the service will be involved. All
acute admissions are screened for potential trial par-
ticipants. Inclusion criteria include the following:
1. Patients over the age of 18 years of age
2. Valid informed consent
3. A diagnosis of acute pancreatitis requiring two of
the following three features [7]:
I. abdominal pain consistent with acute
pancreatitis (acute onset of a persistent, severe,
epigastric pain often radiating to the back)
II. serum lipase activity (or amylase activity) at least
three times greater than the upper limit of normal
III. Characteristic findings of acute pancreatitis on
contrast-enhanced computed tomography
(CECT), magnetic resonance imaging (MR) or
transabdominal ultrasonography
Exclusion criteria
Exclusion criteria include the following [27, 28]:
1. Patients under the age of 18 years of age
2. Comorbidities requiring prolonged antibiotic
therapy—such as infective endocarditis
3. Severely immunocompromised patients—such as
those with human immunodeficiency virus and with
a CD4 count of less than 200 cells/mm3;
neutropenic patients (< 500 neutrophils/mm3)
4. Patients on immunosuppressive therapy
5. Previous thyroid surgery
Intervention
The intervention is the use of a procalcitonin-based al-
gorithm to guide antibiotic use. The algorithm is pre-
sented in Table 1. A study flowchart is shown in Fig. 1.
Patients will be randomised in a 1:1 ratio to receive algo-
rithm-guided or standard care. The randomisation will
be stratified by patient admission route (direct or tertiary
referral).
Intervention arm protocol
This protocol is summarised in the SPIRIT Figure
(Fig. 2). Patients in the intervention arm of the trial
are clearly identified by a trial sticker in the case
notes and drug kardex. Baseline PCT will be mea-
sured on admission (day 0) and the algorithm
followed. For patients admitted to ward-based care,
PCT will be routinely re-assayed on day 4 and at day
7 after admission for those patients remaining in hos-
pital to these time points. Venesection for PCT assay
will be undertaken at the same time as venesection
for routine clinical blood tests: no additional venesec-
tion is required for PCT measurement. For patients
admitted to the critical care unit, PCT will be mea-
sured daily during the acute phase of their illness.
Patients who become symptomatic (at any point)
for infection will undergo PCT assay and follow the
PCT algorithm. Clinically symptomatic patients with
a low PCT will not receive antibiotics. If there is
persisting concern of infection in patients with a low
PCT, the test will be repeated at 24 h. Symptomatic
patients with a raised PCT will receive antibiotics
according to Manchester University Foundation
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Table 1 Procalcitonin-based algorithm to guide antimicrobial use in acute pancreatitis
Evaluation only after enrolment at time of admission to hospital
PCT result < 1.0 μg/L ≥ 1.0 μg/L
Recommendation
on antibiotic use
Do not start antibiotics
Stop antibiotics in patients already
on antimicrobial therapy
Antibiotic intervention
(follow Trust guidelines for prophylaxis or treatment)
Follow-up If there is clinical concern about infection, re-check PCT
after 24 h
Reassess clinical condition
and re-check PCT after 48 h
PCT result < 1.0 μg/L ≥ 1.0 μg/L
Recommendation
on antibiotic use
No antibiotics (or stop antibiotics) Continue antibiotics (or start if not already on antibiotics)
(consider change in antibiotics
if clinically indicated)
Over-ruling the algorithm Empiric antibiotic therapy is permitted in patients not allocated by PCT algorithm to receive antibiotic but decision to be
made only by ITU consultant or HPB consultant surgeon and documented in case notes
HPB hepato-pancreato-biliary, ITU intensive therapy unit, PCT procalcitonin
Fig. 1 PROCAP study flowchart
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Trust antibiotic policy. The PCT algorithm will be
used to guide continuance and discontinuation of
antibiotics. In asymptomatic or symptomatic patients
with positive microbiology results, it is appropriate
to treat positive microbiology results with antibiotics.
PCT should be measured before commencing
antibiotics. PCT measurement should be used to
guide cessation of therapy, either after 48 h, 72 h or
96 h as clinically appropriate. To avoid repeated
short courses of antibiotics, if antibiotic use is trig-
gered by the algorithm, use will be continued for at
least 48 h and then PCT re-assayed. If there is no
clinical evidence of infection at this point, with this
second PCT measurement below threshold, antibiotic
use will be discontinued. If antibiotics have been
prescribed outwith the algorithm, then continued use
will be discussed with the consultant hepato-pan-
creato-biliary (HPB) surgeon under whose care the
patient is being treated or with the Chief Investiga-
tor. After this discussion, antibiotic therapy may be
stopped. The clinician over-ride can be used to ei-
ther start or stop antibiotics in situations of clinical
urgency. Then, the clinician must be either a con-
sultant HPB surgeon or a consultant intensive care
physician, and the reason for over-ride will be docu-
mented. If patients undergo endoscopic, radiological
or surgical procedures which would normally be
undertaken under the cover of antibiotic prophylaxis,
it is appropriate to do this without PCT measure-
ment. If prophylaxis is merged with therapy, then
the PCT measurement for discontinuance will be
triggered.
Selection of PCT cut-off threshold
As with other biomarkers of severity, the usefulness
of PCT is influenced by its chosen threshold value
and the timing and accuracy of the assay. Although
no absolute consensus exists regarding the most ap-
propriate cut-off value for identification of sepsis in
acute pancreatitis, Mofidi et al. [25] report a meta-
analysis of eight studies using PCT cut-off values >
0.5 ng/ml. Taken together with the recommendations
of Schuetz et al. [23] for PCT algorithms in critical
care settings, the optimum threshold for PCT for this
study is 1.0 ng/ml.
PCT assay
The Elecys® BRAHMS fully automated PCT immunoassay
(BRAHMS Assay; Roche Diagnostics Ltd, Rotkreutz,
Switzerland) will be used for the quantitative determination
of procalcitonin in serum.
Fig. 2 SPIRIT figure for the PROCAP trial. EQ-5DL EuroQol EQ-5D, PROCAP PROCalcitonin-based algorithm for antibiotic use in Acute Pancreatitis,
SPIRIT Standard Protocol Items: Recommendations for Interventional Trials
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Standards of general care for all patients with acute
pancreatitis
Standard care will follow the current International
Association of Pancreatology/American Pancreatic As-
sociation (IAP/APA) guidelines for the care of pa-
tients with acute pancreatitis [11]. All aspects of care,
with the sole exception of antibiotic use, will be the
same for patients in both arms of the trial. As PCT
measurement is currently not used regularly in this
or other hospitals in the NHS for patients with acute
pancreatitis, the control arm will represent current
standard care. There will be no procalcitonin meas-
urement in patients allocated to this arm.
Outcomes
i) Primary outcome measure
The primary outcome measure will be the binary out-
come: whether antibiotic use occurs during the index
stay.
ii) Secondary outcome measures
1. Safety non-inferiority endpoint all-cause mortality
2. Days of antibiotic use (for antibiotics initiated
during the index stay) defined as any day (24-h
period) when antibiotics were prescribed on the
patient’s drug prescription chart and administered
3. Clinical infections defined according to the
Centers for Disease Control [29]
4. New isolates of multiresistant bacteria
(Clostridioides difficile, vancomycin-resistant
enterococcus (VRE), methicillin-resistant
Staphylococcus aureus (MRSA), carbapenemase-
producing enterobacteriaceae (CPE))
5. Incidence of multiresistant organism bacteraemia
6. Infection of pancreatic necrosis—defined either as a
result of fine needle aspiration (FNA), radiological
evidence of gas in a peri-pancreatic collection or
positive microbiological cultures from surgical or
post-mortem specimens
7. Use of radiological, endoscopic or surgical
intervention [30]
8. Survival at 90 days; time-to-event (mortality)
survival (Kaplan–Maier)
9. Length of inpatient stay (in total and by level of
care: critical care levels II/III, ward-based care)
10. Re-admission to hospital within 6 weeks of onset of
index episode
11. Episode-related mortality and cause
12. Quality of life assessed by the EQ-5D-5L
questionnaire, at enrollment, discharge and 90
days [31]
13. Cost analysis (from an NHS perspective,
including inpatient resource use)
iii) Measurement of outcomes
The primary (superiority) outcome measure will be
antibiotic use (binary endpoint: yes or no) during the
index stay. Antibiotics prescribed before the index ad-
mission (from the referring hospital or community) will
be recorded at admission but not included in the pri-
mary endpoint.
Sample size
Based on current audit data, 60% of patients admitted
with acute pancreatitis receive antibiotics [13]. A 20%
absolute change in antibiotic use would be a clinically
important difference. This effect of intervention has
been observed in other studies evaluating a procalcitonin
algorithm to guide antibiotic use [23, 28]. A study with
80% power and 5% significance (two-sided) would re-
quire 97 patients in each arm (194 patients in total). The
study will aim to recruit 200 patients. Assuming a 3.6%
mortality rate based on unit audit data [13], the sample
size provides a 6.6% non-inferiority margin for the safety
measure of overall mortality, assuming no change in
mortality, 80% power and 95% CI (one-sided). Previous
randomised trials of the use of a procalcitonin measure-
ment algorithm to guide antibiotic use in a range of clin-
ical settings as well as a Health Technology Assessment
have shown no evidence of harm from this intervention
[23, 24]. However, as there has been no previous evalu-
ation of procalcitonin in an all-comers population of pa-
tients with acute pancreatitis, it is useful to include a
secondary safety outcome with mortality being the most
important factor. The choice of a 6.6% non-inferiority
margin is a pragmatic choice based on the projected
sample size and the estimated population mortality rate
of 3.6%.
Consent process
Valid consent will be obtained for all patients. Consent
procedures will be governed by the Medicines for Human
Use (Clinical Trials) Regulations (2004); Schedule 1, part 5
and by The Medicines for Human Use (Clinical Trials)
Amendment (No. 2) Regulations 2006, No. 2984 [32, 33].
Where available, Trust-appointed translator services will
be used for those patients who are unable to speak or
comprehend English (Additional files 1, 2, 3, 4, 5 and 6).
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Informed consent for patients with capacity
For eligible patients who possess mental capacity, a
member of the research team will make the initial ap-
proach and provide a verbal overview of the study and
what participation will involve. The patient will be pro-
vided with a written information sheet and given the
opportunity to ask questions. After their questions have
been answered, they will have sufficient time to consider
participation; if they are willing to take part in the study,
they will be asked to sign the consent form.
Consent procedures for patients who lack capacity
As acute pancreatitis may be severe, causing disrup-
tion of a patient’s cognitive state or requiring sedation
to facilitate advanced organ support in intensive care,
some potential participants will lack capacity to con-
sent for enrolment. Such patients may still be
enrolled in this study according to the following pro-
cedures. Firstly, a treating clinician who is not part of
the study team will assess the competence of a poten-
tial participant to consent for research. If lack of cap-
acity to consent is confirmed, then valid consent for
enrolment may be obtained from a patient’s legal rep-
resentative. Ideally, this legal representative will be
someone who knows the patient and is able to judge
whether the patient would have agreed to enrolment
in this study. This personal legal representative would
usually be their next of kin or someone with whom
they had a significant relationship, and is willing to
engage with the consent process on the patient’s be-
half. If a personal legal representative is not available,
then the patient’s professional legal representative
may provide consent instead. This will be an inde-
pendent treating clinician who is not part of the
study team. Where a researcher is also the treating
health professional, another member of the research
team, independent of any responsibility for the clin-
ical care of that patient, will be asked to make the
initial approach and/or seek consent from participants
or their legal representative. Patients who recover
sufficiently to understand the explanation of the study
will be asked to consent to continue with the study
procedures as soon as possible or be offered the
chance to withdraw. If the patient chooses to with-
draw from the study procedures, they will be asked
for permission to use their study-related data and for
permission to collect and use outcome data. For all
participants, written consent forms will be signed;
their name filled in and personally dated by the pa-
tient or by their legal representative and by the
Investigator who conducted the consent discussion. A
copy of the signed and dated consent form will be
provided to the patient and/or their legal
representative and another copy filed in the patient’s
medical record.
Withdrawal of consent
Patients can withdraw consent for participation at any
time after enrolment. They do not need to give a reason
and their clinical care will be unaffected. Patients allo-
cated to the procalcitonin arm will not continue to
undergo PCT monitoring of antibiotic use after with-
drawal. Data provided up until the time of withdrawal
will be retained for use in analyses.
Randomisation
Web-based randomisation will be provided by the
Clinical Trials Unit of the University of Edinburgh
(https://www.ed.ac.uk/usher/edinburgh-clinical-trials).
Allocation will be in a ratio of 1:1 to routine or algo-
rithm-guided care. Randomisation will be stratified by
disease severity (mild or moderately severe/severe)
and admission pathway (whether or not the patient
has their index (first) admission with acute pancrea-
titis to the Manchester Royal Infirmary (direct) or is
transferred from another hospital (tertiary transfer)).
A random block size of 4, 6 or 8 will be applied to
each stratum. Patients allocated to either arm will be
identified by a label placed inside and on the front of
the case notes with copy labels used for ward folders.
Data collection
Data collection will use a case report form (CRF) and
include source-verifiable data from patient records,
including procalcitonin test findings and the list of
primary and secondary endpoints. CRFs will be anon-
ymised and contain no individual patient-identifiable
information. Patient-level data will be stored by
screening and trial log numbers. Data will be re-
corded on the timeline of the episode, including time
from onset of symptoms to admission, days in base-
line hospital for tertiary transfers and delay from
admission to enrolment. Patients who are discharged
and re-admitted within 6 weeks will be regarded as a
re-admission for the same episode of care and treat-
ment will be summated. Patients who are re-admitted
will be in the same arm as their original allocation.
Re-admission elsewhere will be a specific question
sought at follow-up (typically at 6 weeks and 90 days).
Patients discharged but subsequently admitted else-
where within 6 weeks will have their pharmacy charts
reviewed wherever possible and antibiotic use sum-
mated. The trial process and data collection are
designed to be minimally burdensome to patients.
Clinically, the 90-day follow-up period will complete
the involvement of the patient in the trial.
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Data storage and transfer
Paper copies of the CRFs will be stored in a locked
cabinet in the Chief Investigator’s office within the
Manchester University Foundation Trust. These cop-
ies will be stored for 12 months after completion of
the trial and then destroyed.
Data will be contemporaneously stored in a password-
protected database, allowing ongoing monitoring of data
quality and completeness. These data will be stored on a
secure desktop computer maintained in the office of the
Principal Investigator.
Anonymised data transfer for analysis will be sent elec-
tronically only to NHS and university email addresses as
anonymised password-protected data.
Analysis plan
Clinical and economic analysis will follow intention-to-
treat principles, as detailed prospectively in a Statistical
Analysis Plan. Endpoints will be assessed using an ap-
propriate general linear model adjusted for stratification
factors; for the primary endpoint, a general linear regres-
sion with logit link will be employed. Missing values will
be addressed by multiple imputation, having appropri-
ately explored the missingness mechanism, and in ac-
cordance with good practice [34]. Chance baseline
imbalances and protocol adherence will be explored
within sensitivity analyses.
The trial will determine whether the use of a procalci-
tonin algorithm reduces antibiotic use during acute pan-
creatitis. Currently, there is clinical uncertainty about
guidelines for reducing antibiotic use in this patient
group, since this draws on indirect evidence. Hence, a
superiority design has been selected, with a null hypoth-
esis that antibiotic use is unchanged by use of the
algorithm.
All-cause mortality in 90 days, re-admission within 6
weeks, adverse events (AEs) and serious adverse events
(SAEs) will be reported and compared between the two
groups. Length of stay in hospital will be reported and
compared using a suitable method (according to its dis-
tribution). Other secondary outcomes will be reported
using appropriate summary statistics.
Data cleaning and analysis will be provided by the
study statistician. Analysis will follow intention-to-treat
principles, with patients analysed according to random-
isation and irrespective of actual use or compliance with
the algorithm. Every effort will be made to retain and in-
clude all patients who are part of the trial. Data will be
analysed using the latest version of STATA (StataCorp).
Economic analysis will be conducted from an NHS
perspective, following similar principles and practices
to the analysis of clinical outcomes. Analysis of costs
will be limited to hospital activity since these will
predominantly determine patient costs during the 90-
day period. A within-trial economic analysis will use
bootstrapped, adjusted, bivariate regression modelling
of costs and quality-adjusted life-years (QALYs), ad-
justed for baseline scores and stratifying variables
[35]. Analyses will be presented as an incremental
cost-effectiveness plane, as a cost-effectiveness accept-
ability curve and by net monetary benefit. An ex-
pected value of perfect information (EVPI) analysis
will also be provided. Given the timeframe of 6 weeks,
discounting of future costs and benefits will not be
applied.
Data Monitoring Committee
An independent Data Monitoring Committee (DMC)
will work in accordance with a DAMOCLES charter
agreed before trial commencement [36]. It is anticipated
that the committee will constitute an independent chair,
a statistician and a patient advocate. The DMC will con-
sider protocol adherence, trial withdrawal and safety
monitoring, and will make recommendations for con-
tinuation of the trial.
The DMC will convene prior to commencement of the
trial and at 6-monthly intervals. Recommendations for
study continuation, modification or termination will be
provided in a confidential report to the Trial Steering
Committee.
Trial Steering Committee
The Trial Steering Committee will include an independ-
ent chairperson and an independent member together
with the Principal Investigator, trial coordinator and stat-
istician. The TSC will meet every 6 months.
Governance arrangements
The sponsor will put in place monitoring and oversight
arrangements appropriate to the needs of the trial.
Adverse event reporting
An adverse event is defined as “any untoward medical
occurrence that may present during the conduct of the
trial, not necessarily having a causal relationship with
the intervention being investigated” [37, 38]. An adverse
event can therefore be any unfavourable and unintended
sign, symptom or disease temporally associated with the
trial.




The research fellow will notify the Principle Investigator
of the adverse event. The Principle Investigator will deter-
mine whether it is an adverse event or a serious adverse
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event. All adverse events will be recorded in line with
European Directive 2001/20/EC [39] and recorded in the
case report form. An annual safety report to the Data
Monitoring Committee will be submitted. SAEs will be re-
ported by email to the Trust quarterly.
Stopping rules
The trial may be stopped temporarily or permanently
(following discussion with the DMC and sponsor) at any
point if the following occur [40]:
1. if there is evidence of trial misconduct noted by the
DMC or by the MFT Research and Innovation
Department
2. if there is evidence of futility or if there is evidence
that the safety non-inferiority endpoint is not met
3. if external scientific evidence emerges to render the
findings of this trial obsolete or irrelevant
Study timeline
The study opened on the 26 July 2018 and it is intended
to recruit for 2 years subject to satisfactory progress as-
sessment by the DMC and the TSC.
Ethics and dissemination
Ethics review
The study was approved by the NHS Health Research
Authority (REC reference 18/NW/0255) on 29 May 2018.
Site-specific approval was granted by the Manchester
University Foundation Trust (Pin B00007) on 5 June 2018.
Study registration
PROCAP was registered with the International Stand-
ard Randomised Controlled Trial Number (ISRCTN
50584992) on 7 February 2018 prior to opening the
study for recruitment.
Reporting of results
Results will be reported at appropriate national and
international meetings and published in peer-reviewed
journals. The authors undertake to report the results of
the completed trial.
Role of the sponsor and funding
There is no external funding for this study. Costs in-
curred for registration of the study with the ISRCTN,
web-based randomisation and the expenses of the
Data Monitoring Committee were met from a Pancre-
atic Research Endowment fund (9033). The study
sponsor had no involvement in study design. The
sponsor is not involved in collection, management,
analysis or interpretation of the data.
The sponsor will not be involved in writing the report
of the decision to submit the report for publication.
The ultimate authority and responsibility for these ac-
tivities rests with the Chief Investigator.
Trial sponsor
Name and contact information for the trial sponsor:
Lynn Webster, Head of Research Office, Manchester
University NHS Foundation Trust, Manchester M13
9RN, UK. Email: lynn.webster@mft.nhs.uk
Discussion
The PROCAP trial tests the hypothesis that a procalcito-
nin-based algorithm to guide initiation, continuation
and discontinuation of antibiotics will lead to reduced
antibiotic use in patients with acute pancreatitis without
an adverse effect upon outcome. The trial explores the
concept that a potentially clinically relevant study can be
undertaken without peer-review funding but can address
an important question.
When complete, PROCAP will be the largest rando-
mised trial of the use of a procalcitonin algorithm to
guide initiation, continuation and cessation of antibiotics
in acute pancreatitis. PROCAP is the only randomised
trial to date to compare standard care of acute pancrea-
titis as defined by the IAP/APA guidelines to patients
having standard care but with all antibiotic prescribing
decisions based on procalcitonin measurement.
Trial status
The current version of the PROCAP protocol is version
1.0. This version was submitted to the North West Re-
search Ethics Committee on 14 March 2018.
The PROCAP trial opened to recruitment on 26 July
2018 and will close to recruitment in July 2020.
Additional files
Additional file 1: Participant information sheet (DOCX 76 kb)
Additional file 2: Patient consent form (DOCX 53 kb)
Additional file 3: Information to GP (DOCX 22 kb)
Additional file 4: Information for consultee (DOCX 42 kb)
Additional file 5: Consultee declaration form (DOC 40 kb)
Additional file 6: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents (DOC 160 kb)
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